95889-09-1

Basic information

• Product Name: 1-Propanone, 1-[4-(bromomethyl)phenyl]-
• Synonyms: 4-bromomethylpropiophenone;1-Propanone,1-[4-(bromomethyl)phenyl]
• CAS NO: 95889-09-1
• Molecular Formula: C10H11BrO
• Molecular Weight: 227.101
• Mol File: 95889-09-1.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1-Propanone, 1-[4-(bromomethyl)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Propanone, 1-[4-(bromomethyl)phenyl]-(95889-09-1)
• EPA Substance Registry System: 1-Propanone, 1-[4-(bromomethyl)phenyl]-(95889-09-1)

Safety Data

• Hazardous Substances Data: 95889-09-1(Hazardous Substances Data)

Upstream product

• 5337-93-9 4'-methylpropiophenone 

Downstream Products

• 894413-35-5 C₁₉H₂₃NO₇ 
• 894413-34-4 C₁₉H₂₄BrNO₆ 
• 894413-33-3 C₁₉H₂₅NO₆ 
• 352233-17-1 (S)-1-(4-hydroxymethylphenyl)-2-methyl-3-(piperidin-1-yl)propan-1-one 
• 352233-15-9 (R)-1-(4-hydroxymethylphenyl)-2-methyl-3-(piperidin-1-yl)propan-1-one 
• 352233-12-6 1-[4-(hydroxymethyl)phenyl]propan-1-one 
• 352233-13-7 4'-acetoxymethylpropiophenone 
• 1361005-73-3 1-(4-(4-methoxybenzyl)phenyl)propan-1-one 

Relevant articles and documents

Synthesis and activity of 2-methyl-3-aminopropiophenones as centrally acting muscle relaxants

Some novel 2-methyl-3-aminopropiophenones were synthesized and their centrally acting muscle relaxant activities were,evaluated for an inhibitory effect on the flexor reflex in rats. The structure-activity relationships are discussed. In this series 2-methyl-3-pyrrolidino-1-(4-trifluoromethylphenyl)-propan-1-one (28) showed significant centrally acting muscle relaxant activity. In addition, the activities of each enantiomer (28-(S) and (R)) were studied along with their acute toxicities. Compound 28-(R) was found to exhibit more potent activity and weaker acute toxicity than 28-(S). Accordingly, compound 28-(R) (NK433) is under development as a novel centrally acting muscle relaxant.

COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES

Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one oximine, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses.

PHENAZINE AND QUINOXALINE SUBSTITUTED AMINO ACIDS AND POLYPEPTIDES

Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a phenazine or quinoxaline substituent. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides.